Acute Kawasaki Disease Therapy
- 5 Downloads
Purpose of review
We review the acute management of patients with Kawasaki disease (KD), including adjunctive primary therapies and the treatment of patients with resistance to intravenous immunoglobulin (IVIG).
IVIG administered within 10 days of fever in patients with (KD decreases the risk of coronary artery complication from ~ 25% to < 5%. However, patients at high risk of IVIG resistance or those with coronary changes at diagnosis may benefit from additional primary anti-inflammatory therapies.
All patients with suspected KD should be treated with aspirin and IVIG (2 g/kg). Patients at high risk of treatment resistance and/or coronary complications may benefit from adjunctive treatments, including corticosteroids or infliximab. Patients with persistent fever after initial IVIG treatment are at high risk of coronary complications and usually are retreated with IVIG. Corticosteroids, infliximab, cyclosporine, anakinra, and cyclophosphamide have also been described in patients refractory to initial therapy, though optimal therapy in this high-risk group remains unknown.
KeywordsKawasaki disease Adjunctive treatment IVIG resistance Intravenous immunoglobulin Infliximab Corticosteroids
Compliance with Ethical Standards
Conflict of Interest
Audrey Dionne declares that she has no conflict of interest. Jane W. Newburger declares that she has no conflict of interest. Kevin G. Friedman declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 2.• McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927–99. The recent and updated scientific statement of the American Heart Association on the management of patients with Kawasaki disease provides recommendations for the initial evaluation, treatment in the acute phase, and long-term management of patients with Kawasaki disease.CrossRefGoogle Scholar
- 4.Baumer JH, Love SJ, Gupta A, Haines LC, Maconochie I, Dua JS, et al. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2006;(4):Cd004175.Google Scholar
- 5.• Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984;2(8411):1055–8. This clinical trial, performed in Japan, was the first to demonstrate the efficacy of intravenous immunoglobulin in the treatment of Kawasaki disease for reducing coronary artery complications.CrossRefGoogle Scholar
- 15.Hamada H, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet. 2019;393(10176):1128–37.CrossRefGoogle Scholar
- 16.• Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379(9826):1613–20. In this prospective, multi-center, randomized trial, the addition of prednisolone to the standard regimen of intravenous immunoglobulin improved coronary artery outcomes in patients with severe Kawasaki disease in Japan.CrossRefGoogle Scholar
- 18.Friedman KG, Gauvreau K, Hamaoka-Okamoto A, Tang A, Berry E, Tremoulet AH, et al. Coronary artery aneurysms in Kawasaki disease: risk factors for progressive disease and adverse cardiac events in the US population. J Am Heart Assoc. 2016;5(9).Google Scholar
- 21.Son MBF, Gauvreau K, Kim S, Tang A, Dedeoglu F, Fulton DR, et al. Predicting coronary artery aneurysms in Kawasaki disease at a North American Center: an assessment of baseline z scores. J Am Heart Assoc. 2017;6(6).Google Scholar
- 23.Dionne A, Burns JC, Dahdah N, Tremoulet AH, Gauvreau K, de Ferranti SD, Baker AL, Son MB, Gould P, Fournier A, Newburger JW, Friedman KG. Treatment intensification in patients with Kawasaki disease and coronary aneurysm at diagnosis. Pediatrics. 2019;143(6) pii:e20183341. https://doi.org/10.1542/peds.2018-3341. Epub 2019 May 2
- 26.Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR. Infliximab plus intravenous immunoglobulin (IVIG) versus IVIG alone as initial therapy in children with Kawasaki disease presenting with coronary artery lesions: is dual therapy more effective? Pediatr Infect Dis J. 2018;37(10):976–80.CrossRefGoogle Scholar
- 28.Portman MA, Dahdah NS, Slee A, Olson AK, Choueiter NF, Soriano BD, et al. Etanercept with IVIg for acute Kawasaki disease: a randomized controlled trial. Pediatrics. 2019:e20183675.Google Scholar
- 38.Lang BA, Yeung RS, Oen KG, Malleson PN, Huber AM, Riley M, et al. Corticosteroid treatment of refractory Kawasaki disease. J Rheumatol. 2006;33(4):803–9.Google Scholar